Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain

Jönsson, Bengt; Horisberger, Bruno; Bruguera, Miguel; Matter, Lukas (1991). Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain. International journal of technology assessment in health care, 7(3), pp. 379-402. Cambridge University Press 10.1017/S0266462300005754

[img]
Preview
Text
S0266462300005754.pdf - Published Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview

The availability and efficacy of recombinant deoxyribonucleic acid yeast-derived hepatitis-B vaccine, at a price much lower than the previously available plasma-derived hepatitis-B vaccines against hepatitis-B virus infections, motivate a new cost-benefit analysis of hepatitis-B vaccination. Spanish data were used to calculate direct and indirect costs of hepatitis-B infection and the costs and benefits of different vaccination strategies in defined risk groups of the Spanish population. A vaccination program will reduce direct expenditures for hepatitis B if the attack rate in the target population is higher than 4.9%. If indirect costs are included, the threshold for cost saving is reduced to 0.9%. The results are sensitive to the price of the vaccine, the duration of protection, assumptions about consequences for quality of life, and to indirect costs.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Matter, Lukas

ISSN:

1471-6348

Publisher:

Cambridge University Press

Language:

English

Submitter:

Marceline Brodmann

Date Deposited:

03 Aug 2020 11:48

Last Modified:

03 Aug 2020 11:48

Publisher DOI:

10.1017/S0266462300005754

BORIS DOI:

10.7892/boris.115131

URI:

https://boris.unibe.ch/id/eprint/115131

Actions (login required)

Edit item Edit item
Provide Feedback